Published: Mar 11, 2021
New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation
TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021
RELEASE trial on track to report topline results in Q1 2021
Topline results from two ongoing trials with BXCL701 in aggressive forms of prostate cancer and advanced solid tumors are expected in mid-2021
Company to host conference call today at 8:30 a.m. ET
NEW HAVEN, Conn., March 11, 2021 (GLOBE NEWSWIRE) BioXcel, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its quarterly results for the fourth quarter and full year ended December 31, 2020
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides .
BioXcel TherapeuticsMarch 11, 2021 GMT
New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation
TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021
RELEASE trial on track to report topline results in Q1 2021
Topline results from two ongoing trials with BXCL701 in aggressive forms of prostate cancer and advanced solid tumors are expected in mid-2021
BioXcel Therapeutics Appoints June Bray to Board of Directors Former Allergan executive brings extensive global regulatory experience across multiple therapeutic areas
March 01, 2021 07:00 ET | Source: BioXcel Therapeutics BioXcel Therapeutics New Haven, Connecticut, UNITED STATES
NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) BioXcel Therapeutics, Inc. ( BioXcel or the Company ) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of June Bray to its Board of Directors. Ms. Bray brings over forty years of extensive U.S. and global regulatory experience in the healthcare industry and most recently served as Senior Vice President, Global Regulatory Affairs and Medical Writing at Allergan.
MTN. LAKE PARK â Peggy Jean Damon, 72, of Mountain Lake Park died on Friday, Dec. 18, 2020, at home, surrounded by her family.
Born on Oct. 31, 1948, in Cumberland, she was the daughter of Betty E. (Jeffers) Glotfelty of Oakland and the late Donald B. Glotfelty.
Peggy enjoyed reading, knitting, her âKissin Cousinâ reunions and monthly luncheons with her dear friends. Most of all, she enjoyed spending time with her family, Friday night dinners at her home and traveling with her children and family. Her favorite destination, other than home, was the beach. Peggy had a very special connection with her great-nieces and -nephews. They will remember her for chocolate chip cookies, cinnamon rolls and âBill.â